Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy ... propelled by its popular injections. "We are pleased with the performance ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...

Ozempic's expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a gradual loss of kidney function.

Three of Novo’s revolutionary GLP-1 drugs were selected for the government price-setting program: Ozempic injections for Type ... to Medicare patients. Novo Nordisk’s position in the American ...